Virus & Viral Vectors
Channeling the Power of Viruses and Viral Vectors to Advance Human Health
As a leading global CDMO offering fully integrated development and manufacturing services for live viruses and viral vectors, we offer a seamless journey from pre-clinical to commercial launch.
With extensive experience supporting plasmids and a wide range of virus types and cell lines, Recipharm Advanced Bio meets the changing needs of adeno-associated virus (AAV), lentivirus, and oncolytic virus therapeutics. We utilize a platform-based approach across various species and serotypes to efficiently meet your program’s needs.
Supporting Diverse Virus & Viral Vector Projects
The applications for viruses and viral vectors are extensive and ever-changing. Recipharm Advanced Bio has deep and growing scientific expertise across a range of product types.
Viral Vectors
The Recipharm Advanced Bio team has extensive experience with viral vector design, upstream and downstream process development, comprehensive analytics, and benchtop- and pilot-scale viral vector manufacturing.
Our expertise includes the following vector types:
- Adenovirus (Ad)
- Adeno-associated virus (AAV)
- Herpes simplex virus (HSV)
- Retrovirus
- Lentivirus
- Baculovirus
Viral Vaccines
Our broad cell line experience – including VERO, HEK293, and A549 – is supported by adherent and suspension cell cultivation and serum-free and egg-based system expertise.
We support your project throughout its lifecycle and are skilled in working with numerous virus types, including:
- Adenovirus (human and NHP)
- Respiratory syncytial virus (RSV)
- Newcastle disease (NDV)
- Influenza (Flu)
- Dengue (DENV)
- Infectious bursal disease (IBDV)
- Infectious bronchitis virus (IBV)
- Measles (rubeola)
- Poxviruses (MVA, Fowlpox)
Oncolytic Virus Therapeutics
As a leading expert handling the complexity of oncolytic virus (OV) therapeutic manufacturing and development, Recipharm Advanced Bio advances your therapy with the specialized infrastructure and in-depth expertise needed to successfully deliver OVs to the clinic and beyond.
Our oncolytic virus expertise includes:
- Arenavirus
- Adenovirus (Ad)
- Herpes simplex (HSV)
- Fowlpox (FPV)
- Modified vaccinia Ankara (MVA)
- Newcastle disease (NDV)
- Measles (MV)
- Vaccinia/modified vaccinia Ankara (MVA)
- Vesicular stomatitis (VSV)
- Egg-based, chick embryo fibroblasts (CEF) and continuous cell lines (including HEK293/T, A549, VERO, and MRC-5)
Comprehensive Virus & Viral Vector Solutions
Recipharm Advanced Bio offers fully integrated solutions for viral vector manufacturing. Our expertise in process development, scale-up, and GMP production ensures a seamless pathway for advancing your viral-based therapies. Explore our supporting services below.
Our in-house vector design and process development expertise delivers consistently high-quality final pDNA products
Recipharm Advanced Bio’s high-quality cell and virus banks are developed in multiple expansion formats and sizes to meet GMP and client requirements
Recipharm Advanced Bio has extensive experience providing GMP sterile fill-finish services for virus and viral vector customers worldwide
Virus & Viral Vector Resources
Advancing Your Program Together
Your program isn’t just another project—it’s a breakthrough in the making. At Recipharm Advanced Bio, we bring deep scientific expertise, innovative thinking, and a problem-solving mindset to every partnership. Whether scaling a complex process, navigating regulatory pathways, or optimizing for commercial success, we’re here to collaborate, adapt, and deliver with excellence.
Let’s push the boundaries of possibility together and bring transformative therapies to patients faster.